Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.